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The capacity to act as an electron donor and acceptor makes iron an essential cofactor of many vital processes. Its balance in
the body has to be tightly regulated since its excess can be harmful by favouring oxidative damage, while its deﬁciency can impair
fundamentalactivitieslikeerythropoiesis.Inthebrain,anaccumulationofironoranincreaseinitsavailabilityhasbeenassociated
with the development and/or progression of diﬀerent degenerative processes, including Parkinson’s disease, while iron paucity
seems to be associated with cognitive deﬁcits, motor dysfunction, and restless legs syndrome. In the search of DNA sequence
variations aﬀecting the individual predisposition to develop movement disorders, we scanned by DHPLC the exons and intronic
boundary regions of ceruloplasmin, iron regulatory protein 2, hemopexin, hepcidin and hemojuvelin genes in cohorts of subjects
aﬀected by Parkinson’s disease and idiopathic neurodegeneration with brain iron accumulation (NBIA). Both novel and known
sequence variations were identiﬁed in most of the genes, but none of them seemed to be signiﬁcantly associated to the movement
diseases of interest.
1.Introduction
Iron is an essential element for cells, but when in excess
or not properly stored, it can be toxic by the Fenton
reaction that generates reactive oxygen species. It is highly
probable that an impaired iron metabolism exerts a role
in the pathogenesis of diﬀerent neurodegenerative processes
sharing the common feature of an aberrant iron distribution
in selective brain areas. This seems to hold true especially for
movement disorders. It is known that regions of the brain
that are associated with motor functions usually show higher
iron levels than other areas [1] indicating the relevance
of iron homeostasis for these cerebral sections. Increased
total iron or at least increased non-ferritin-bound labile
iron seems to be closely associated to Parkinson’s disease
(PD) [2, 3]. This has been documented in the substantia
nigra (SN) of PD patients by many authors and with
varied technologies [4–7]. Furthermore, iron chelation by
clioquinol or sequestration by ferritin overexpression [8]
protected dopaminergic neurons from chemically induced
degeneration, while mice on iron-rich diet show increased
sensitivity to the MPTP treatment [9]. A solid support to2 Parkinson’s Disease
the causal relationship between iron and the development
of neurodegeneration comes also from the observation that
diﬀerent hereditary neurodegenerative pathologies charac-
terized by extrapyramidal symptoms are associated with
defects in genes involved in iron homeostasis; mutations
in the genes coding for ferritin light chain (FTL) or for
ceruloplasmin (CP) lead to adult-onset diseases termed
neuroferritinopathy [10, 11] and aceruloplasminemia [12],
respectively, both included in the neurodegeneration with
b r a i ni r o na c c u m u l a t i o n( N B I A )g r o u pa n dc h a r a c t e r i z e d
by excess deposit of iron, especially in the basal ganglia.
Friedeich ataxia is linked to variations in the frataxin
gene which codes for a mitochondrial protein presumably
involved in iron-sulphur cluster assembly [13]. Diﬀerent
animal models have been recently described which further
strengthen the idea that impairment of iron management
may be an early event in the route leading to increased
oxidative stress and neurodegeneration. Iron Regulatory
Protein (IRP)-2 knock-out mice show ataxia, tremors, and
bradykinesia [14], while mice heterozygous for the deletion
of the FTH gene have an altered ferritin to iron ratio, as
described also in the brain of PD patients [15, 16].
The large majority of PD and other movement dis-
orders are idiopathic and not associated with mendelian
inheritance; nonetheless, genetic and environmental factors
surely inﬂuence the individual risk to develop these type of
diseases. On the basis of the postulated contribution of iron
maldistribution to the development of these pathologies,
genes coding for proteins participating to systemic and
cerebral iron management can be interesting targets for
association studies aimed at deﬁning allelic variants aﬀecting
the population susceptibility for movement disorders. This
hypothesis has experimental support: for example, some
polymorphisms and haplotypes of the CP [17], of the
transferrin[18],andofthehaptoglobingene[19]werefound
to be signiﬁcantly associated with PD in cohort studies, and
it was suggested that they may contribute to iron-induced
oxidative stress. On the other hand, the numerous studies
on mutations of the hemochromatosis gene HFE in PD gave
more conﬂicting results [20–24].
Here, we report the results from an extensive genetic
analysis of some of the key genes of iron metabolism such
as CP, IRP2, Hepcidin (HAMP), and Hemopexin (HPX),
in a large cohort of PD patients and in a smaller group of
idiopathic neurodegeneration with brain iron accumulation
(NBIA) cases.
2.MaterialandMethods
2.1. Patients and Controls. DNA for PD patients and con-
trols was provided from the DNA Bank of the Parkinson
Institute, Istituti Clinici di Perfezionamento, Milan, Italy
(http://www.parkinson.it/dnabank.html). PD patients were
selected because they had a positive family history (ﬁrst-
degree and/or second-degree relative aﬀected) or had an
early onset before 40 years of age. The clinical diagnosis of
PD was established according to the UK Parkinson Disease
Society Brain Bank criteria [25, 26]. Patients with idiopathic
NBIA were from Ospedale Galliera, Genova, and from the
Section of Internal Medicine, University of Verona, Italy. An
informedconsenttotheuseofthegenomicDNAforresearch
purposes was provided by all participants. The study was
approved by the local Ethics Committee.
2.2. Mutation Scanning. The genes of interest were ampliﬁed
with standard protocols with the primers described in the
supplementary information (See Table 1SI in supplemem-
tary material available online at doi: 10.4061/2011/827693).
Prior to DHPLC analysis, heteroduplexes were obtained
by denaturing the PCR-ampliﬁed products at 95◦Cf o r
5min and cooling down to 56◦C over one hour. DHPLC
screening was performed on a WAVETM DNA Fragment
Analysis System (Transgenomic, Omaha, NE, USA) at the
temperatures indicated in the supplementary data (Table
1SD).Hetero-andhomodimersanalysiswascarriedoutwith
an acetonitrile gradient formed by mixing buﬀers A (0.1M
TEAA) and B (0.1M TEAA, 25% acetonitrile). DNA samples
with an altered DHPLC proﬁle were re-ampliﬁed in a new
PCR reaction, conﬁrmed on an DHPLC run and analyzed by
direct DNA sequencing. The nomenclature was established
according to den Dunnen and Antonarakis, 2003.
3. Results and Discussion
3.1. Parkinson’s Disease. We recently described the incidence
of sequence variations in the genes coding for the heavy and
light chains of ferritin [27] and for mitochondrial ferritin,
(Castiglioni et al. [28]) in patients aﬀected by PD and idio-
pathic NBIA, and these results are recapitulated in Tables 1
and 2. We extended our analyses to other genes involved
in the management of iron balance and traﬃcking and
associated with iron-related neurodegeneration in patients
or animal models. The DHPLC scanning of the 19 exons of
CP in 103PD patients revealed 24 nucleotide substitutions,
of which six were not reported in databases. Eleven of them
were in the coding region, 1 in the 3  UTR, and 12 in the
introns(Table 1).Manyofthem(10)wererare,withanallelic
frequencybelow1%.Thec+1632A>T(D544E)substitution,
which was previously found to be associated with PD
[17], was detected at the heterozygous state in 10 patients
(4.85%). This frequency is not signiﬁcantly diﬀerent from
t h a tr e p o r t e di nd b S N P( http://www.ncbi.nlm.nih.gov/)f o r
studies based on populations of European origin (Hap Map
CEU 7.5%) and similar to the one reported by Hochstrasser
for the control population of 180 subjects. Only three
intronic variations were found in more than 5% of the
population. For two of them (IVS12-15delG and IVS15-
12T>C), the incidence was signiﬁcantly lower than that
reported in databases, based on a lower number of subjects.
The relevance of such results needs to be conﬁrmed in wider
populations, even though very similar frequencies (18.2%)
werefoundforthesametwosubstitutionsin11patientswith
idiopathic NBIA.
T h ea n a l y s i so fI R P 2g e n ei n5 0 P Dp a t i e n t sr e s u l t e d
in the identiﬁcation of 7DNA variations, one new and six
already known. One lies in the 5  UTR, 1 synonymous in
exon 21, and 5 in the introns. Most of them were rare (below
2%), and the others had allelic frequencies similar to thoseParkinson’s Disease 3
Table 1: Allelic frequencies of the sequence variations identiﬁed in FTL, FTH, FTMT, CP, IRP2, HPX, and HAMP genes in PD patients and
controls.
Gene PD CNT DNA variation Gene position AF AF AF
NN PD CNT DB
FTL 252 180 c+163T>C ex. 2 19.05% (96/504) 25% (90/360) 52% (1)
c+522C>T ex. 4 0.20% (1/504) none
c+398A>C (H133P) ex. 4 0.20% (1/504) none
c−129delC IRE-L 0.20% (1/504) none
c−37T>C5   UTR 0.20% (1/504) none
IVS2+50C>T int. 2 0.40% (2/504) none
IVS2+60T>G int. 2 0.40% (2/504) 0.56% (2/360)
IVS2+66G>C int. 2 0.20% (1/504) none
FTH 252 180 c+161A>G (K54R) ex. 2 none 0.56% (2/360)
IVS2+29 ins GTCATAG2 int.2 3.57% (18/504) 4.44% (16/360)
IVS2+23 G>A int.2 0.20% (1/504) none
FTMT 332 342 c+134C>A (P45H) ex.1. 1.05% (7/664) 2.49% (17/684)
c+273C>T (S91S) ex.1 0.15% (1/664) none
c+506A>T (N169I) ex.1 none 0.15% (1/684)
c+554G>A (G185D) rs35482405 ex.1 0.15% (1/664) none 1.5% (2)
c+646G>C (V216L) ex.1 0.15% (1/664) 0.29% (2/684)
c+667G>T (A223S) ex.1 0.15% (1/664) 0.29% (2/684)
c+745C>T3   UTR 0.15% (1/664) none
CP 103 none c+484A>T (T162S) ex. 3 0.49% (1/206)
c+788A>G (N263S) ex. 5 0.49% (1/206)
c+1430C>T (P477L) rs35331711 ex. 8 0.49% (1/206) 1.3% (2)
c+1632A>T (D544E) rs701753 ex. 9 4.85% (10/206) 7.5% (1)
c+1652C>T (T551I)3 rs61733458 ex. 9 4.37% (9/206) nd
c+1950A>C (G650G) rs1053709 ex. 11 3.88% (8/206) 5.1% (1)
c+2446G>A (V816L) ex. 14 0.49% (1/206)
c+2522C>G (T841R)3 rs56033670 ex. 14 0.97% (2/206) nd
c+2571C>T (Y857Y) ex. 15 0.49% (1/206)
c+2793 A>G (L931L) rs34987997 ex. 16 0.49% (1/206) 2.2% (3)
c+2991T>C (H997H) rs34394958 ex. 17 2.91% (6/206) 7.9% (3)
IVS1+41G>A rs3736282 int. 1 6.31% (13/206) 11.4% (3)
IVS2+20C>T rs17847023 int. 2 4.85% (10/206) 10.9% (3)
IVS4−14C>T rs34067682 int. 4 2.43% (5/206) 6.5% (3)
IVS5−51A>G rs34003547 int. 5 4.37% (9/206) 2.3% (3)
IVS7−47G>A int. 7 0.97% (2/206)
IVS9−38T>C rs6799507 int. 9 1.46 % (3/206) 0.8% (1)
IVS10+62T>C rs35149808 int. 10 0.49% (1/206) 0.0% (3)
IVS10+113C>T rs35516209 int. 10 4.37% (9/206) 4.5% (3)
IVS14+17G>A rs35593818 int. 14 3.88% (8/206) 6.2% (3)
IVS12−15delG rs34861155 int. 12 17.96% (37/206) 36.4% (3)
IVS15−12T>C rs16861582 int. 15 15.05% (31/206) 32.5% (1). 20.8% (4)
IVS17−78T>C int. 17 0.49% (1/206)
c+3335C>T rs34228141 3  UTR 2.43% (5/206)
IRP2 50 none c+2616C>T (A872A) rs13180 ex. 21 21% (21/100) 35% (1)
c−89C>T4 rs954144 5  UTR 28% (28/100) 44% (1)
IVS4−56G>C int. 4 2% (2/100)
IVS5+22A>C rs2938672 int. 5 1% (1/100) 0% (1)
IVS5+73delC rs11372841 int. 5 1% (1/100) nd
IVS7+19A>G rs3817092 int. 7 10% (10/100) 16.1% (1)
IVS12+50G>A rs9788758 int. 12 2% (2/100) nd4 Parkinson’s Disease
Table 1: Continued.
Gene PD CNT DNA variation Gene position AF AF AF
NN PD CNT DB
HPX 103 94 c+1017C>T (S339S) ex. 9 None 0.5% (1/188)
IVS1+24C>T rs35862450 int. 1 13.1% (27/206) 19.7% (37/188)
IVS1−32T>A int. 1 1%(2/206) None 26.4% (5)
IVS1−41C>T int. 1 None 0.5% (1/188)
IVS8−26A>G int. 8 None 0.5% (1/188)
HAMP 50 50 c−72C>T 1.0% (1/100) None
c+55G>A (A19T) ex 1 1.0% (1/100) None
Genomic DNA from PD patients and controls was PCR ampliﬁed and scanned by DHPLC. PD: Parkinson’s disease, CNT: controls, AF: allelic frequency, DB:
database.
FTL: ferritin light chain (NM 000146.3), FTH: ferritin heavy chain (NM 002032.2), FTMT: mitochondrial ferritin (NM 026286.2), CP: ceruloplasmin
(NM 000096.3), IRP2: iron regulatory protein 2 (NM 004136.2), HPX: hemopexin (NM 000613.2), HAMP: hepcidin (NM 021175.2), ex: exon, int: intron,
(1) HapMap-CEU, (2) AGI ASP POPULATION, (3) JAR CEPH-PANEL, (4) AFD EUR PANEL, (5) pilot1.CEU.
Table 2: Allelic frequencies of the sequence variations identiﬁed in CP and IRP-2 genes in sNFT patients.
Gene NBIA DNA variation Gene position AF AF AF
NBIA CNT DB
FTL 11 c+163T>C (L55L) rs2230267 ex. 2 31.82% (7/22) 25% (90/360) 52% (1)
FTH 11 c+161A>G (K54R) ex. 2 None 0.56% (2/360)
FTMT 11 c+134C>A (P45H) ex.1 4.55% (1/22) 2.49% (17/684)
CP 11 c+1632A>T (D544E) rs701753 ex. 9 9.09% (2/22) 7.5% (1)
c+1652C>T (T551I) rs61733458 ex.9 4.55% (1/22) nd
IVS1+41G>A rs3736282 int. 1 13.64% (3/22) 11.4% (2)
IVS2+20C>T rs17847023 int. 2 18.2% (4/22) 10.9% (2)
IVS10+91C>G rs41267873 int. 10 4.55% (1/22) 0.0% (2)
IVS12−15delG rs34861155 int. 12 18.2% (4/22) 36.4% (2)
IVS15−12T>C rs16861582 int. 15 18.2% (4/22) 32.5% (1)
IRP2 11 c−89C>T rs954144 5  UTR 22.95% (6/22) 44% (3)
c+2616C>T (A872A) rs13180 ex. 21 21% (4/22) 35% (1)
Genomic DNA from idiopathic NBIA patients was PCR ampliﬁed and scanned by DHPLC. sNFT: suspected Neuroferritinopathies, AF: allelic frequency, DB:
database.
FTL: ferritin light chain (NM 000146.3), FTH: ferritin heavy chain (NM 002032.2), FTMT: mitochondrial ferritin (NM 026286.2), CP: ceruloplasmin
(NM 000096.3), IRP2: iron regulatory protein-2 (NM 004136.2), ex: exon, int = intron, (1) HapMap-CEU, (2) JAR CEPH-PANEL, (3) pilot1.CEU.
reported in databases. All the 10 exons of the HPX gene
were analysed by DHPLC in 103 patients and 94 controls.
We found 1 synonymous substitution in exon 9 and 4
in the introns. The IVS1+24C>T variation was common
(mean allelic frequency 16.2%) with no diﬀerence between
patients and controls. All the other ones were rare, and the
IVS1-32T>A was clearly underrepresented when compared
to available information in the database (1% versus 26,4%).
The study of the HAMP and HJV genes was limited to exon
1a n de x o n s2a n d3 ,r e s p e c t i v e l y ,d u et op r o b l e m sw i t h
DNA ampliﬁcation. However, these exons cover a signiﬁcant
portion of the coding sequence in both genes. No variation
in the HJV gene was found in the 50 patients and 50 controls
analysed, while 2 substitutions were found in HAMP gene,
both in the patient group, 1 nonsynonymous change in
exon 1 (c+55G>A, A19T) and 1 at the base immediately
preceding the transcription start site.
3.2. Idiopathic NBIA. Eleven cases of idiopathic NBIA were
investigatedforDNAsequencevariationsintheCPandIRP2
genes (Table 2). Seven diﬀerent SNPs were detected in CP;
all of them were already described and had frequencies not
signiﬁcantly diﬀerent from the ones we found in PD patients
or available in the database. Only the intronic substitution
IVS2+20C>Twasmorefrequentthanexpectedsince4outof
11 patients were heterozygous for it (18,2%) as compared to
the 4.85% frequency in the PD cohort and the 10,9% in the
database. In the IRP2 gene, only two variations were found
(c−89C>T,c+2616C>T)andwithfrequenciescomparableto
those found in PD patients.
4. Conclusion
Homozygous mutations of CP, IRP2, and HPX were found
to cause neurodegeneration in patients [12] or in animal
models [14] and Morello et al. [29]. Here, we show that these
genes present DNA variations and polymorphisms, but none
of them has an allelic frequency, which allows us to infer a
possibleeﬀectupontheindividualrisktodevelopthedisease.
Also the c+1632A>T (D544E) substitution in the CP gene,Parkinson’s Disease 5
which has been found to be linked to PD and to increased
echogenicity of the SN [17], does not appear to be diﬀerently
present in our PD population than in-database studies.
HAMP and HJV encode proteins with a central role in the
regulationofsystemicironhomeostasisandshowsomeDNA
variations, but none of them is evidently associated with PD
disorders. As for idiopathic NBIA, our cohort was very small
andthedatalimited, buttheydonotsuggestanevidentasso-
ciation of DNA variations in CP and IRP2 genes with such
disorders. Even though iron metabolism probably exerts an
important role in the development of the neurodegenerative
processes which underline several types of movement
disorders, the genetic data we generated until now seem to
exclude a simple and direct involvement of key genes of iron
management in modifying the individual predisposition to
PD and NBIA. More in depth studies are required to verify
the existence of more complex genetic interactions that
could link some of the identiﬁed nucleotide variations with
brain iron deregulation and neurodegeneration.
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